

**NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND
EQUIPMENT JOINT STOCK
COMPANY**

No: ~~4.40~~./DNA/CBTT

SOCIALIST REPUBLIC OF VIETNAM
Independence — Freedom — Happiness

Nghe An, Date 20 month 10 year 2026.

**TO : State Securities Commission
Hanoi Stock Exchange**

III. Disclosing organization

1. Organization name: Nghe An pharmaceutical Medical Material and Equipment Joint Stock Company (“The Company”).
2. Stock Code: NTF
3. Head office Address: No 16, Nguyen Thi Minh Khai, Thanh Vinh Ward, Nghe An province.
4. Phone: 0238.384.1642
5. Website: <https://dnapharma.com.vn/>
6. Contents of information disclosure:

The company would like to provide an explanation for the accumulated after-tax profit in Q3/2026 is loss, compared to the same period in 2025, changed above 10% as follows:

Indicator	Quarter III/2026 (VND)	Quarter III/2025 (VND)	Variance (VND)	Ratio	Accumulated 9M/2026 (VND)	Accumulated 9M/2026 (VND)	Ratio
After- tax profit on FS	2,357,254,085	706,491,236	1,650,762,849	Up 234%	2,859,636,517	2,907,171,762	Down 2%

The Company's post-tax profit in **Q3/2026** experienced strong growth compared to the same period last year, primarily driven by the following core factors:

- **Product Portfolio Restructuring:** The Company proactively shifted its sales mix toward product groups with higher gross profit margins (such as contract manufacturing for third parties). This strategic pivot optimized the efficiency of the existing production infrastructure without incurring significant capital expenditures.

- **Selling Price Adjustments to Enhance Gross Profit:** The Company reviewed and implemented reasonable price increases for its flagship pharmaceutical lines. This measure aimed to boost revenue, expand the gross profit margin per unit product, and realign with the brand's premium market positioning.
- **Temporary Stabilization of Raw Material Supply Chain:** During the reporting period, the supply of Active Pharmaceutical Ingredients (APIs) remained stable. The enterprise formulated proactive sourcing strategies to minimize the risk of supply chain disruptions. Consequently, factory manufacturing operations ran continuously, ensuring timely delivery to major partners and eliminating overhead costs associated with production downtime.

Additionally, the recent stabilization of domestic fuel prices directly mitigated inbound raw material transport and outbound logistics expenses. The combination of a steady supply chain and reduced logistical overhead directly maximized the profit margins of our pharmaceutical product lines in **Q3/2026**.

Sincerely,

Recipients:

- As above;
- Chairman of the Board of Directors;
- Member of the Board of Directors;
- Filed: Office.



TRAN CONG VINH